Navigation Links
Galectin Therapeutics Exclusive Interview for the Interlinked Investment News Channel on InterlinkedTV

(PRWEB) December 02, 2013

Galectin Therapeutics was one of the presenting companies interviewed at the recent FSXinterlinked Investment Conference, held at the Ritz Carlton in Marina Del Rey, California.

During the interview Galectin Therapeutics Executive Chairman, Jim Czirr, said "Galectin Therapeutics is a pharmaceutical company. We are working on drugs to treat untreatable disease at the moment. Diseases like nash, fatty liver disease with fibrosis, cirrhosis of the liver, as well as cancer. This protein called galectin is implicated in those diseases and is responsible for the advancement of the diseases. By inhibiting them or by blocking them we are able to affect the disease in a positive way and improve the patient’s life. In the case of fibrosis, we have evidence that we can reverse it, in the case of cancer, we show great improvement in immune system function with our product."

The interview was conducted by FSXinterlinked Investment Conference Host, Michael Fugler, and is available on the FSXinterlinked channel on InterlinkedTV and more information is available at Galectin Therapeutics’ website.

Galectin Therapeutics, formerly Pro-Pharmaceuticals, is a development-stage company, engages in the discovery and development of therapeutics for the treatment of cancer, liver, microbial, and inflammatory diseases.

About FSXinterlinked Investment Conference
FSXinterlinked is the premier investment conference organization in the United States. Founded as Financial Services Exchange (FSX) in 1983, it is a national organization comprised of independent FINRA broker/dealer firms and private equity fund managers. With quarterly investment conferences hosted throughout the U.S., FSXinterlinked creates a forum for emerging growth companies seeking capital to present to a nationwide network of financial investment professionals.

The FSXinterlinked network of independent broker/dealers has a combined sales force of thousands of accredited investors looking to invest in companies of all sizes and industries. To date, more than $3 billion has been raised for presenting companies through the FSXinterlinked network. FSXinterlinked’s exclusive network of FINRA firms makes the investment conferences the ideal setting for private and public companies seeking mezzanine financing, funding for private placements, IPOs, secondary financing and pipes, exposure, and more. For more information, visit

Interlinked is a global investment community of accredited investors, emerging growth companies, and resource partners. Interlinked offers an efficient way for companies to maximize exposure and access a private network of funding sources and verified service providers. For investors, Interlinked provides a secure environment to find, vet and engage companies, and communicate with members. Interlinked gives members exclusive access to a proprietary investment platform, which integrates virtual data rooms, video news, a service provider marketplace, an event directory, and customized marketing services, including email marketing, video production, public relations and more. For more information, visit:

Safe Harbor Statement
This press release may contain information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, trends, analysis, and other information contained in this press release, including words such as “anticipate,” “believe,” “plan,” “estimate,” “expect,” “intend,” and other similar expressions of opinion, constitute forward-looking statements. Any such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from any future results described within the forward-looking statements. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company’s reports filed with the Securities and Exchange Commission. The forward-looking information provided herein represents the Company’s estimates as of the date of the press release, and subsequent events and developments may cause the Company’s estimates to change. The Company specifically disclaims any obligation to update the forward-looking information in the future. Therefore, this forward-looking information should not be relied upon as representing the Company’s estimates of its future financial performance as of any date subsequent to the date of this press release.

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Targeted therapeutics for colon cancer to be presented at AACR meeting
2. The Ludwig Institute for Cancer Research announces launch of iTeos Therapeutics SA
3. FORMA Therapeutics teams with TGen Drug Development
4. Media alert: 24th EORTC - NCI - AACR Symposium Molecular Targets and Cancer Therapeutics
5. Research shows potential of microneedles to target therapeutics to the back of the eye
6. Cancer vaccine Special Focus series published in Human Vaccines & Immunotherapeutics
7. Scientist receives $2.8 Million to study cell signaling mechanism and develop potential therapeutics
8. Ontario Genomics Institute invests in stem cell technology at Tissue Regenerative Therapeutics
9. Liver Diseases Therapeutics Market - New Industry Research Report Published by Transparency Market Research
10. Global Peptide Therapeutics Market - New Market Research Report Published by Transparency Market Research
11. Corena Therapeutics Launched Coresatin, a Nonsteroidal Cream Used to Treat Critical Skin Conditions and Infections
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... ... lower prices in an early celebration of the early holiday shopping season. Starting ... $29.95 each (normally $33.95 ea). Black Friday promotional pricing is in addition to ...
(Date:11/24/2015)... PA (PRWEB) , ... November 24, 2015 , ... ... now certified to offer their patients the many benefits of the revolutionary BIOLASE ... the sharp cutting and scraping tools traditionally used by a dentist in ...
(Date:11/24/2015)... ... November 24, 2015 , ... New patients who wish to seek treatment ... dental implants at her Mississauga, ON practice. Dr. Williams has been providing dental ... dental implants. , Missing teeth can lead to a variety of complications if ...
(Date:11/24/2015)... , ... November 24, 2015 , ... Charitable giving is ... donations are made in the last five weeks of the year totalling over $358 ... in 2012 to connect the nation’s charities with those individuals who want to “give ...
(Date:11/24/2015)... , ... November 24, 2015 , ... In an ... restrictions and variables that determine which patients are or are not eligible for bariatric ... have a BMI over 40, are more than 100 pounds overweight, or have a ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... Nov. 24, 2015  In the pharmaceutical industry, companies ... effort to quickly uncover new insights, tactics and strategies ... --> --> However, organizations often find ... project and ensure that all rules and regulations are ... Another major barrier to efficiently launching market research projects ...
(Date:11/24/2015)... NEWPORT NEWS, Va. , Nov. 24, 2015 /PRNewswire/ ... that they have signed an agreement for DILON to ... select geographies across the globe. The signing of this distribution ... GE,s Discovery NM750b Molecular Breast Imaging system and is ... ways to provide better healthcare solutions for clinicians and ...
(Date:11/24/2015)... Nov. 24, 2015   HeartWare International, Inc . ... miniaturized circulatory support technologies that are revolutionizing the treatment ... Chief Executive Officer Doug Godshall is scheduled ... Annual Healthcare Conference on December 1, 2015 at 3:00 ... in New York . ...
Breaking Medicine Technology: